What are your top takeaways in GU Cancers from ASCO 2026?

1. A-DREAM (Alliance A032101): Can We Give Patients a Break from ADT?

For men with APMS prostate cancer who achieve exceptional biochemical responses to testosterone suppression (TS) plus an ARPI, can treatment be safely interrupted to allow testosterone recovery and improved quality of life?

Single-a...

LBA1 — PROTEUS

Dr. Mary-Ellen Taplin and colleagues presented at the ASCO 2026 Plenary Session and simultaneously in the NEJM (Perioperative Apalutamide in High-Risk Localized Prostate Cancer | New England Journal of Medicine) the phase 3 PROTEUS trial, a study of 2,109 patients with high/very high ...

I would say the PROTEUS trial and add the ASTRO response.

In addition to PROTEUS and TALAPRO-3 (which will be highlighted by many people), I also found these three topics interesting:

• ABBV-969: dual-targeting ADC of PSMA and STEAP1
• ACTION trial (225Ac-PSMA-617)
• CONVERGE-01 trial (225Ac-PSMA-targeting radioantibody)

• PROTEUS (localized prostate cancer)
• TALAPRO-3 (metastatic hormone-sensitive prostate cancer)
• EV-302 (metastatic urothelial carcinoma)